We’ve rebranded some of our products, learn more ›
CODEX® is now PhenoCycler, Phenoptics™ is now Phenolmager.
Spatial Signature Development That Meets Your Throughput Needs
The PhenoImager® instruments leverage Akoya’s patented multispectral imaging (MSI) and spectral unmixing technology to deliver a highly accurate quantitative assessment of diverse immune phenotypes within the tumor microenvironment (TME), not only capturing both tissue context and spatial distribution at single cell resolution.
These fast, user-friendly yet powerful whole slide imaging platforms are ideally suited to help researchers develop spatial signatures at their desired scale.
Instruments
PhenoImager HT 2.0 – Spatial Signatures at Your Scale
The PhenoImager HT 2.0 is the fastest and most highly cited imager for spatial phenotyping and spatial signature development. Featuring whole-slide multispectral scanning with onboard spectral unmixing, this system can be easily integrated into high-throughput workflows to accommodate projects, regardless of your scale .
Power of multispectral imaging in a high throughput workflow: - Brightfield and fluorescence imaging (up to 9 colors)
- 6-plex whole slide scans in less than 12mins (see newly launched PhenoCode Signature Panels)
- Onboard spectral unmixing parallelized with scanning
- 400+ slides/week throughput with walk-away automation
PhenoImager Fusion – Spatial Signatures Within Your Reach
PhenoImager Fusion functions as a standalone ultrafast imager ideal for standard throughput and high-plex spatial phenotyping applications. PhenoImager Fusion also integrates with the PhenoCycler™ instrument (formerly CODEX®) for spatial discovery at scale.
Enhanced Workflow Efficiency: - Brightfield and fluorescence imaging (up to 7 colors)
- 6-plex whole slide scans in under 20mins (see newly launched PhenoCode Signature Panels)
- 4-slide capacity
- Easy integration with the PhenoCycler instrument to enable ultrahigh-plex (100+ biomarkers/slide) imaging
Related Publications
High Endothelial Venules Predict Response to PD‑1 Inhibitors Combined with Anti‑angiogenesis Therapy in NSCLC
This study from researchers at Wuhan University explored the predictive value of tumor‑associated high endothelial venules (TA‑HEVs) in combination therapy using immunofluorescence staining and showed frequency of HEVs is positively correlated with tumor‑infiltrating stem‑like CD8+ T cells.
ERK1/2 Phosphorylation Predicts Survival Following Anti-PD-1 Immunotherapy in Recurrent Glioblastoma
This study from Northwestern University showed using mIF that ERK1/2 phosphorylation (p-ERK), a marker of MAPK/ERK pathway activation, is predictive of overall survival following adjuvant PD-1 blockade in two independent rGBM patient cohorts
Determinants of Response to CDK4/6 Inhibitors in The Real-world Setting
Scientists from Roswell Park Comprehensive Cancer Center explored distinct pathological and biological features of HR+/HER2− breast cancer associated with response to CDK4/6 inhibitors, using mIF staining to show the selective loss of phosphorylated RB with treatment consistent with the action of CDK4/6 inhibitors
Related Resources
Key Reviews
Literature
Webinars
Key Reviews
Literature
Webinars
